Gene · 4261
Papers3,496
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,496
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The NLRP3 inflammasome in viral infection (Review). | Mol Med Rep | 2023 | 37417336 | PubTator, text mining | PubMed |
| Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome. | Front Immunol | 2023 | 37415984 | PubTator, text mining | PubMed |
| Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. | Cell | 2023 | 37413990 | PubTator, text mining | PubMed |
| Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity. | Front Immunol | 2023 | 37388742 | PubTator, text mining | PubMed |
| Treatment mechanism of immune triad from the repurposing drug against COVID-19. | Transl Med Aging | 2023 | 37388715 | PubTator, text mining | PubMed |
| Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability-Lessons from Colorectal Cancer. | Genes (Basel) | 2023 | 37372349 | PubTator, text mining | PubMed |
| Identification and Interpretation of eQTL and eGenes for Hodgkin Lymphoma Susceptibility. | Genes (Basel) | 2023 | 37372322 | PubTator, text mining | PubMed |
| Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy. | Biomolecules | 2023 | 37371564 | PubTator, text mining | PubMed |
| The NLRP3 inflammasome: contributions to inflammation-related diseases. | Cell Mol Biol Lett | 2023 | 37370025 | PubTator, text mining | PubMed |
| A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations. | Cancer Med | 2023 | 37366281 | PubTator, text mining | PubMed |
| [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37357002 | PubTator, text mining | PubMed |
| [Gray zone lymphoma: five cases report and literature review]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37356987 | PubTator, text mining | PubMed |
| Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. | Cell Rep | 2023 | 37355988 | PubTator, text mining | PubMed |
| High-throughput identification of regulatory elements and functional assays to uncover susceptibility genes for nasopharyngeal carcinoma. | Am J Hum Genet | 2023 | 37352861 | PubTator, text mining | PubMed |
| Time-dependent recruitment of GAF, ISGF3 and IRF1 complexes shapes IFNα and IFNγ-activated transcriptional responses and explains mechanistic and functional overlap. | Cell Mol Life Sci | 2023 | 37347298 | PubTator, text mining | PubMed |
| 3D genome organization and epigenetic regulation in autoimmune diseases. | Front Immunol | 2023 | 37346038 | PubTator, text mining | PubMed |
| Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. | Cancers (Basel) | 2023 | 37345056 | PubTator, text mining | PubMed |
| CRISPR-Cas9-mediated disruption of B2M and CIITA genes eliminates HLA class I and II expression in human induced pluripotent stem cells (MUSIi001-A-2). | Stem Cell Res | 2023 | 37343428 | PubTator, text mining | PubMed |
| Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes. | J Exp Med | 2023 | 37341991 | PubTator, text mining | PubMed |
| Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study. | Front Oncol | 2023 | 37333831 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4261/papers?page=19